4 documents

Read All
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

ARRY-502: Additional Phase II data

Additional data from a pre-defined subset of patients with an elevated median baseline value of fractional exhaled nitric oxide (FeNO) in a double-blind, U.S. Phase II trial showed that twice-daily 200 mg oral ARRY-502 significantly...
Read More
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Forest Laboratories Inc. (NYSE:FRX) was up $0.42 to $44.41 on Friday after FDA approved Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product will be available in the...
Read More
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

ARRY-502: Phase II data

A double-blind, U.S. Phase II trial in 184 patients with mild to moderate persistent allergic asthma showed that twice-daily 200 mg oral ARRY-502 for 4 weeks met the primary endpoint of improving pre-bronchodilator FEV1 from...
Read More
00:52 , Jul 24, 2013 |  BC Extra  |  Top Story

Array gains on Phase II asthma data

Shares of Array BioPharma Inc. (NASDAQ:ARRY) jumped on Tuesday after the biotech reported that twice-daily oral ARRY-502 for four weeks met the primary endpoint in a 184-patient Phase II trial to treat persistent allergic asthma....
Read More